Patents by Inventor Donald Paul Matthews

Donald Paul Matthews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-aminobenzonitrile selective androgen receptor modulators
    Patent number: 8658693
    Abstract: The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: February 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: Jonathan Edward Green, Prabhakar Kondaji Jadhav, Venkatesh Krishnan, Donald Paul Matthews, Ashraf Saeed, Gregory Alan Stephenson
  • Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
    Patent number: 7968587
    Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142.
    Type: Grant
    Filed: November 6, 2007
    Date of Patent: June 28, 2011
    Assignee: Eli Lilly and Company
    Inventors: Konstantinos Gavardinas, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews
  • Tetrahydrocarbazole derivatives useful as androgen receptor modulators
    Patent number: 7935722
    Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: May 3, 2011
    Assignee: Eli Lilly and Company
    Inventors: Kevin Robert Fales, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews, David Andrew Neel, Edward C R Smith
  • Tricyclic steroid hormone nuclear receptor modulators
    Patent number: 7803814
    Abstract: The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: September 28, 2010
    Assignee: Eli Lilly and Company
    Inventors: Konstantinos Gavardinas, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews
  • TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS
    Publication number: 20100069404
    Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142.
    Type: Application
    Filed: November 6, 2007
    Publication date: March 18, 2010
    Inventors: Konstantinos Gavardinas, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews
  • Sulfonamide derivatives as PPAR modulators
    Patent number: 7655641
    Abstract: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: February 2, 2010
    Assignee: Eli Lilly and Company
    Inventors: Scott Eugene Conner, Lynn Stacy Gossett, Jonathan Edward Green, Winton Dennis Jones, Jr., Nathan Bryan Mantlo, Donald Paul Matthews, Daniel Ray Mayhugh, Daryl Lynn Smith, Jennifer Ann Vance, Xiaodong Wang, Alan M Warshawsky, Leonard Larry Winneroski, Jr., Yanping Xu, Guoxin Zhu
  • TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS
    Publication number: 20100022550
    Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).
    Type: Application
    Filed: June 21, 2006
    Publication date: January 28, 2010
    Applicant: CELLECTIS
    Inventors: Kevin Robert Fales, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews, David Andrew Neel, Edward C.R. Smith
  • TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS
    Publication number: 20090149445
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
    Type: Application
    Filed: July 15, 2008
    Publication date: June 11, 2009
    Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
  • Tricyclic steroid hormone nuclear receptor modulators
    Patent number: 7482344
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: January 27, 2009
    Assignee: Eli Lilly and Company
    Inventors: Michael Joseph Coghlan, Prabhakar Kondaji Jadhav, James Joseph Droste, Jonathan Edward Green, Donald Paul Matthews
  • Tricyclic steroid hormone nuclear receptor modulators
    Patent number: 7411072
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: August 12, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
  • MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR)
    Publication number: 20080167310
    Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
    Type: Application
    Filed: October 3, 2007
    Publication date: July 10, 2008
    Inventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky, Maria Rosario Gonzalez-Garcia
  • Modulators of peroxisome proliferator activated receptors (PPAR)
    Patent number: 7282501
    Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: October 16, 2007
    Assignee: Eli Lilly and Company
    Inventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6265581
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: July 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.-3 adrenergic agonists
    Patent number: 6093735
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta..sub.3 adrenergic agonists
    Patent number: 6075040
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: June 13, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 6060492
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: May 9, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 5939443
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Donald Paul Matthews, John Hampton McDonald, III, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.-3 adrenergic agonists
    Patent number: 5840738
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 5786356
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: July 28, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Anthony John Shuker, Mark Alan Winter